Real-World Experience With Acute Infusion Reactions to Ustekinumab at 2 Large Tertiary Care Centers

BACKGROUND: Ustekinumab is approved for Crohn’s disease and Ulcerative colitis with acute infusion reactions reported at a rate of 0.9%–4.5%. METHODS: A retrospective chart review was conducted on inflammatory bowel disease (IBD) patients experiencing an acute infusion reaction to ustekinumab at 2 l...

Descripción completa

Detalles Bibliográficos
Autores principales: Spencer, Elizabeth A, Kinnucan, Jami, Wang, Julie, Dubinsky, Marla C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927818/
https://www.ncbi.nlm.nih.gov/pubmed/36798650
http://dx.doi.org/10.1093/crocol/otaa022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927818/
https://www.ncbi.nlm.nih.gov/pubmed/36798650
http://dx.doi.org/10.1093/crocol/otaa022

Ejemplares similares